Study Objective

This trial evaluates the safety and tolerability of MK-1084, a targeted therapy developed by Merck. The primary focus is to assess how adverse events are managed when MK-1084 is combined with standard therapy in patients with non‑small cell lung cancer (NSCLC). Safety data will inform decisions on advancing to Phase 2 and Phase 3, making early results highly influential on the subsequent development strategy.

Exploration of Therapeutic Effect

The investigators will examine the impact of MK-1084 in combination therapy on tumor response rates. NSCLC is characterized by high tumor heterogeneity, limiting the efficacy of existing standard treatments; therefore, a drug with a novel mechanism of action that demonstrates activity could substantially broaden therapeutic options. This may contribute to a shift toward a personalized treatment paradigm.

Clinical Design and Phase

The study employs a combined Phase 1/2 design to capture early safety (Phase 1) and efficacy signals (Phase 2) concurrently. The trial is currently recruiting and commenced on April 30, 2026. This parallel design aims to shorten development timelines and optimize resource utilization.

Market and Competitive Landscape

The current NSCLC treatment market is dominated by combinations of immune checkpoint inhibitors and targeted therapies. If MK-1084 demonstrates synergistic activity with existing regimens, Merck could strengthen its portfolio and increase market share. Conversely, safety concerns would necessitate a reassessment of investor relations and partnership strategies.